Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Treatment discontinuation due to gastrointestinal events occurred in a minority of patients, and overall, serious adverse events were similar to those with the placebo
This mechanism would bypass the gastrointestinal tract and provide steady-state drug levels over an extended period
Viking Theraputics: The GLP-1 start-up If you are a real risk-taker, Viking Theraputics (VKTX +2.74%) is a money-losing pharma start-up with GLP-1 drugs in clinical trials
25% of customers reported side effects and most appear to resolve on their own
US$ 21.37
US$ 22.98
US$ 27.47
